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Abstract
Background: The P-glycoprotein (P-gp), an ATP binding cassette transmembrane transporter, is
expressed by astrocytes in the adult brain, and is positively modulated during astrogliosis. In a
search for factors involved in this modulation, P-gp overexpression was studied in long-term in vitro
astroglial cultures.
Results: Surprisingly, most factors that are known to induce astroglial activation in astroglial
cultures failed to increase P-gp expression. The only effective proteins were IFNγ  and those
belonging to the IL-6 family of cytokines (IL-6, LIF, CT-1 and CNTF). As well as P-gp expression,
the IL-6 type cytokines - but not IFNγ  - stimulated the expression of endogenous CNTF in
astrocytes. In order to see whether an increased intracellular level of CNTF was necessary for
induction of P-gp overexpression by IL-6 type cytokines, by the same cytokines analysis was carried
out on astrocytes obtained from CNTF knockout mice. In these conditions, IFNγ  produced
increased P-gp expression, but no overexpression of P-gp was observed with either IL-6, LIF or
CT-1, pointing to a role of CNTF in the intracellular signalling pathway leading to P-gp
overexpression. In agreement with this suggestion, application of exogenous CNTF -which is
internalised with its receptor - produced an overexpression of P-gp in CNTF-deficient astrocytes.
Conclusions: These results reveal two different pathways regulating P-gp expression and activity
in reactive astrocytes, one of which depends upon the intracellular concentration of CNTF. This
regulation of P-gp may be one of the long searched for physiological roles of CNTF.
Background
Recent studies have reported expression of the transmem-
brane transporter P-glycoprotein (P-gp) in astrocytes, in
addition to the previously determined endothelial locali-
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sation. This second cellular location raises new questions
as to the function of P-gp in the brain because, whereas
endothelial P-gp clearly participates directly in the trans-
port of substrates across the blood-brain barrier for a
number of identified substrates [1–4], the physiological
roles and substrates of its astroglial counterpart are un-
known. One potential clue to these issues is the fact that
P-gp expression is stimulated in astrocytes activated by
various brain insults [5].
P-gp consists of a group of closely related, intrinsic mem-
brane proteins encoded by the multidrug-resistance (mdr)
genes [6]. It acts as an ATP-driven efflux pump [7] that ac-
cepts a wide range of structurally different substrates,
among which are drugs, hormones, corticosteroids, cy-
tokines or phospoholipids [8–10]. The adult brain is a
major site of expression of P-gp [2,11–15], and it had long
been exclusively associated to the endothelial cells in cap-
illary walls [2,4,16], until astrocytic endfeet were identi-
fied as another specific location in vivo [17,18], and in vitro
[19].
In order to start deciphering the physiological role of P-gp
in astrocytes, we have chosen to study its increase in ex-
pression in reactive astrocytes, by looking for the effects of
a wide variety of molecules known to induce astroglial ac-
tivation in in vitro culture conditions. This involved, in
particular, several agents that had also been shown to
stimulate P-gp expression in other cell types, such as Inter-
feron-α  and -γ  (IFN-α , γ ) [20–22], Tumor Necrosis Factor
alpha (TNF-α ) [21,23] and dibutyryl-cyclic-AMP [24], and
also a number of other compounds classically used to in-
duce astroglial differentiation in vitro. Surprisingly, only a
few of these factors drove astroglial P-gp expression, indi-
cating that P-gp overexpression is not just related to astro-
glial differentiation, but appears as a specific response to
certain stimuli. This increase in P-gp expression thus
seems to characterize a specific stage of differentiation,
which, in one pathway at least, also involves an increased
concentration of the ciliary neurotrophic factor (CNTF).
The two proteins may be even more functionally linked to
each other since some of the "astrogliotic" stimuli able to
increase P-gp expression require CNTF as a key intracellu-
lar signal.
Results
Enriched astroglial cell cultures were readily obtained
from cerebral hemispheres of Swiss mice and of CNTF
knockout mice, and maintained for several weeks without
signs of cell alteration.
Expression of P-gp in primary astrocyte culture
Astrocytes in culture expressed P-glycoprotein as early as
24 h after plating. The RT-PCR performed on a fragment
of the P-gp transcript yielded a 167-bp product (Fig. 1a),
present in all astrocyte samples and in the MES-SA/MX2
cells used as a positive control. At the protein level, the re-
sults varied over time: until the 4th day in vitro (div), the
antibody raised against P-gp detected a band at about 120
kDa; from the 6th div a doublet was detected at about
160–170 kDa; finally, at 15 div this doublet became pre-
dominant and its expression increased (Fig. 1b).
Effects of molecules promoting astrogliosis on P-gp expres-
sion
Among the agents known to activate astrocytes ("astrogli-
otic factors") that were tested for modulating P-gp expres-
sion, most failed to alter it (Table 1). This was in particular
the case for dBcAMP, IL-1β , LPS, NGF, RA, rhIFNα , rhT-
GFα  and TNFα . In contrast, all the cytokines that belong
to the IL-6 family induced a 50% or more increase in ex-
pression of P-gp in long-term astrocyte culture. This effect
was dose-dependent and was modulated by α  receptor
subunits, when relevant. For instance, rrCNTF was ineffi-
cient when used alone at 30 ng/ml in long-term cultures.
However, an increase in the cellular content of P-gp was
observed in a significant and reproducible manner when
100, and even further 250 ng/ml of rCNTF were used (Fig.
2a). As previously described for the effects of rCNTF on
other astroglial markers of differentiation [25], addition
Figure 1
MDR1mRNA and P-gp expression in astroglial cul-
tures. a/ RT-PCR showing MDR1mRNA. b/ Western blot-
ting using rabbit anti-P-gp polyclonal antibody demonstrating
the presence of P-gp as early as 2 div. Between 2 div and 5
div, a band is observed at about 120 kDa (lower black
arrow); a doublet appears at 6 div at about 150–170 kDa
(black arrows); the band corresponding to the mature form
of P-gp, is expected at 170 kDa (grey arrow), and becomes
increased after 15 div.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/20
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of 200 ng/ml of c-myc-sCNTFRα  induced a potentiation
of the effects, and an increase of P-gp cellular content was
then observed with the lowest concentration of rCNTF
studied (10 ng/ml), and maintained for all other concen-
trations used (data not shown). Addition of rhLIF and
rhCT-1, in the culture medium provoked an increase of
about 1.5 to 2-fold of P-gp cellular content (Fig. 2b). Ad-
dition of rmIL-6 at concentrations below 40 ng/ml in the
culture medium was inefficient, but a significant increase
of P-gp intracellular content was observed when this con-
centration was used (Fig. 2c). Addition of rhsIL-6Rα  to the
culture medium induced a major potentiation of the ef-
fects, since, in these conditions, all concentrations used
triggered a significant increase in P-gp content (Fig. 3).
Selective blockade of P-gp transporter activity was studied
using two different specific blockers, S9788 and vera-
pamyl. When used at concentrations of 5 µM and 10 pM,
a complete blockade of the effects of all IL-6 family cy-
tokines was observed. Even the presence of the specific α
receptor subunit for IL-6 and CNTF failed to reverse the
neutralising effects of S 9788 (Fig. 5) and verapamyl (data
not shown).
Besides the IL-6 family of cytokines, the only compound
to trigger P-gp overexpression in astrocytes was IFNγ  (Fig.
6a). This IFNγ  effect was very likely direct since hLIF05,
which inhibits the LIF receptor pathway, could not reverse
it.
Regulation of P-gp expression in CNTF-/- astrocytes
The progressive maturation of P-gp during development
and the regulation of its expression by members of the IL-
6 family of cytokines are two features that P-gp shares with
CNTF in astrocytes (see discussion section). Moreover,
like P-gp, CNTF regulation is very specific, since, among
different molecules that normally trigger astrogliosis, only
those belonging to the IL-6 family provoked an increase of
CNTF (Fig. 7). We, therefore, explored the possibility of a
functional link between the two molecules by analysing
whether the presence of endogenous CNTF in astrocytes
was required for the observed modulation of P-gp expres-
sion by IL-6 type cytokines and IFN-γ . This was tested by
analysing the effects of the cytokines in astrocytes taken
from CNTF knockout mice. In these cultures, the modula-
tion of P-gp by LIF, CT-1 or IL-6 (even in presence of its
specific α  receptor subunit) was completely lost (Fig. 4).
In contrast, addition of rrCNTF (250 ng/ml) produced a
significant increase of P-gp intracellular level. In the CNTF
-/- astrocytes, addition of IFN-γ  to the medium triggered
an increase of P-gp cellular level comparable to that ob-
served in wild-type astrocytes, underlining its direct effect
on P-gp modulation (Fig. 6b).
Figure 2
Effect of cytokines on P-gp cellular content in mature
astrocytes. a/ Addition of 100 and 250 ng/ml rCNTF during
24 h induced a statistically significant increase as compared to
untreated controls (+51.7% ± 15.6, factorial ANOVA signifi-
cant at 95%, t-test p < 0.01** and +75.7 ± 30, factorial
ANOVA significant at 95%, t-test p < 0.05*, respectively). b/
Addition of rhLIF during 24 h induced a significant increase of
P-gp expression both at 10 and 30 ng/ml (+42.7 % ± 14, fac-
torial ANOVA significant at 95%, t-test p < 0.05* and +54.35
% ± 12, factorial ANOVA significant at 95%, t-test p < 0.01**
respectively). The same pattern of regulation was observed
with CT-1 at 10 ng/ml (+69.6 % ± 24, factorial ANOVA sig-
nificant at 95%, t-test p < 0.01**). c/ Addition of rmIL-6 elic-
ited a significant increase of P-gp intracellular content at 40
ng/ml (+68.8 % ± 10, factorial ANOVA significant at 95%, t-
test p < 0.001***)BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/20
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Discussion
The main result of this study is the demonstration of a
close interaction between expression of two intrinsic as-
troglial proteins, the IL-6 cytokine CNTF and the ATP-
binding cassette transmembrane transporter P-gp. Besides
a parallel development of expression, the concentration of
the two proteins appears, in particular, to be similarly in-
creased following stimulation by IL-6-type cytokines
whereas a number of other agents eliciting activation of
astrocytes are ineffective. Moreover, astroglial expression
of CNTF appeared to be necessary for the effects of IL-6-
type cytokines on P-gp expression. Reciprocally, blockade
of P-gp activity eliminated the effects of cytokines, even
CNTF, on its own expression, suggesting a functional link
between the two systems.
P-gp and CNTF may be involved together in a specific type 
of astrocytic activation
The recent discovery of P-gp expression on astrocytic end-
feet [17,18] and its induction after a stress [5] has raised
the issue of a role of this protein in astrocytes. To address
this issue, we have undertaken, here, an analysis of the ex-
pression of P-gp over time during development and of its
stimulation in mature cells. The first feature in this study
is the striking similarity between the results obtained for
astroglial P-gp and those previously gathered on the astro-
glial cytokine CNTF. Indeed, P-gp and CNTF seem to share
parallel modulations of expression both during develop-
ment and under specific stimulations. First, like CNTF
[26], P-gp is not detectable in the early stages of postnatal
development in the central nervous system. Both proteins
are detected from P7, and their concentration levels grad-
ually increase, reaching a plateau at P28 [15,26]. Results
obtained in in vitro astroglial cultures are also indicative of
a parallel maturation of the two proteins. P-gp, both at
mRNA and protein levels, was expressed in our study as
soon as after 24 hours in culture, but Western blot studies
revealed that the protein detected in those early cultures
did not have the 170 kDa mature form [15], that became
predominant only after 14 days, the point at which astro-
cytes exhibit a mature phenotype (see discussion in 25). A
very similar time course of expression was observed previ-
ously for CNTF [25]. Before 7 days in vitro, immature as-
trocytes did not express detectable levels of CNTF,
whereas at 14 div, when astrocytes form a confluent mon-
olayer and express high levels of GFAP, they exhibit a sig-
nificant intracellular content of CNTF.
In vitro, astrocytes activation experiments further indicate
a parallel regulation of the two proteins. Even though in
vivo models of astrogliosis have revealed a concomitant
overexpression of both proteins [5,27], most factors that
readily induce astroglial activation in vitro fail to increase
their expression [28,29] and the present study). Indeed,
Figure 3
Potentiation of IL-6 effects on P-gp expression by
adding its specific α  receptor subunits. Addition of solu-
ble IL-6R induced a major potentiation of rmIL-6 whatever
the concentration of the factor used.
Figure 4
Effect of cytokines of the IL-6 family on P-gp intracel-
lular content in CNTF-/- astrocytes. Only rrCNTF (250
ng/ml) provoked a significant increase in P-gp intracellular
content (+43.8 % ± 20, factorial ANOVA significant at 95%, t-
test p < 0.01**).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/20
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for both proteins, only IFNγ  (in the study by Carroll and
colleagues, 31, for CNTF) and the IL-6 family cytokines
could trigger a quantifiable increase in expression in astro-
cytes (this study).
All these results suggest that the overexpression of CNTF
and P-gp participate in the definition of a particular stage
of astroglial differentiation. So-called astrogliosis has long
been considered as a discrete "activation" stage of astro-
cytes, on the basis of its characteristic morphological fea-
tures. However, more recent studies exploring the
expression of specific molecules have questioned this
view, drawing attention to the fact that reactive gliosis var-
ies qualitatively and quantitatively depending on both the
nature of the injury and the microenvironment of the in-
jury site (see references and discussion 30 and 31). The
nature of the injury and the microenvironment necessary
for the differentiation stage of astrocytes that involves
CNTF and P-gp overexpression is, at this point, a matter of
speculation. It is interesting to note, nevertheless, that, in
agreement with the in vitro data, intra-cerebral administra-
tion of adenovirus recombinant for CNTF produced an in-
crease in the astroglial content of endogenous CNTF
without triggering massive "astrogliotic" morphological
changes [32].
Intracellular concentration of CNTF as a modulator of P-
gp expression in astrocytes
Out of the present study, the relationship between CNTF
and P-gp in astrocytes appears as a functional link rather
than as a mere co-regulation. Indeed, one main result ob-
tained in this study was the apparent requirement of an
intracellular level of CNTF for the expression of P-gp to be
modulated by IL-6-type cytokines, since this modulation
was not seen in cells that did not express the CNTF gene.
The only exogenous cytokine that remained effective in
CNTF-/- cells was CNTF itself. This may be explained by
the fact that exogenous CNTF, when bound to its receptor,
is internalised into the cells [33]. As discussed by these au-
thors, endocytosed CNTF may be active inside the cell, as
has been demonstrated for neurotrophins/Trks complexes
(see 34 for a review). Through this mechanism, therefore,
restoration of an intracellular content of CNTF may be-
come sufficient to trigger a increased P-gp expression.
How an increase in the cellular content of CNTF increases
the expression of P-gp was not directly addressed in this
study. Nevertheless, a number of elements help to suggest
a working hypothesis. A direct transcriptional role of
CNTF on the P-gp gene promoter is unlikely for three rea-
sons. First, it has been well demonstrated that the intrac-
ellular signalling systems triggered by CNTF are essentially
similar to those triggered by LIF [35,36]. Why would LIF
not be effective in CNTF-/- astrocytes when CNTF is,
Table 1: Modulation of P-gp expression by agents that induce 
astroglial reactivity.
Treatment Concentration Effect
dBcAMP 0,5 mM - 3.1 ± 8
IL-1β 50 ng/ml +10.5 ± 11
Lesion / - 12.1 ± 8
LPS 1 µg/ml + 2.3 ± 8
NGF 10 ng/ml - 21.7 ± 22
RA 10-7 M - 28.6 ± 20.2
rhIFN-β 600 U/ml -20 ± 11
rhIFNγ
rhTGFα
300 U/ml
50 ng/ml
+50 ± 30
-9 ± 5
TNFα 100 ng/ml + 7.6 ± 9.1
rhCT-1 10 ng/ml + 69.6 ± 24**
rhLIF 30 ng/ml + 54.3 ± 12**
rmIL-6 40 ng/ml +68.8 ± 10***
RmIL-6 50 ng/ml +220.28 ± 22***
+
rhsIL-6R 500 ng/ml
rrCNTF 250 ng/ml + 75.7 ± 30*
*: ANOVA significant at 95%, t-test p < 0.05; **: ANOVA significant at 
95%, t-test p < 0.01; ***: ANOVA significant at 95%, t-test p < 0.001.
Figure 5
E f f e c t  o f  P - g p  b l o c k e r s .  Addition of the P-gp blocker
S9788 in the culture medium blocked completely the effect
of rrCNTF at 250 ng/ml (-1.5 vs. +75.7 %), rhLIF at 30 ng/ml
(-11.5 vs. + 54.3%) and rhCT-1 at 30 ng/ml (-2.5 vs. +26.1%)
on P-gp expression in astrocytes.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/20
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would be difficult to explain in case of a direct transcrip-
tional effect. Second, our results demonstrate that the con-
trol of P-gp expression requires a modulation of the
intracellular content of the cytokine. Third, the stimula-
tion of P-gp expression by cytokines was blocked with an-
tagonists of the activity of the transporter. This indicates
that the regulation of P-gp depends upon its own activity
and suggests the existence in astrocytes of a positive feed-
back of the molecule upon its own expression. Such a sug-
gestion is concordant with the well demonstrated positive
feedback of P-gp activity upon its expression in various tu-
mor cells, in the presence of non-organic substrates like
cytotoxic drugs [37,38].
In a mechanistic model based upon this hypothesis, en-
dogenous astroglial CNTF would most likely not appear
as a usual cytokine activating signalling pathways after
binding to a transmembrane receptor system, but as a
"sensor", itself modulated by extrinsic cues. The changes
induced in the intracellular concentration of this "sensor"
might affect the activity of the P-gp transmembrane trans-
porter and, eventually, lead to a modulation of its gene ex-
pression (Fig. 8). Such a scheme suggests a physiological
role for CNTF, a cytokine which, because of the absence of
a signal peptide and the lack of a quantifiable release in
the culture medium of cells that synthesise it [32,39,40],
was not thought to play a physiological role in the ab-
sence of a lesion [41]. Whether P-gp is the only target of
the effects of CNTF, or just the first one identified is obvi-
ously an open question at this point.
Figure 6
Evidence of another P-gp-CNTF-independent-regula-
tion pathway. a) Addition of IFNγ  at 300 U/ml in the cul-
ture medium induces an increase of the P-gp cellular level
(+48.42%  ± 30). This increase remains unchanged by the
addition of the hLIF05, partial LIF receptor inhibitor at two
concentrations (+69% ± 35 at 0.5 µg/ml and +76% ± 30 at 5
µg/ml). b) The same effect is observed in CNTF-deficient
astrocyte culture. Addition of IFNγ  at the same concentra-
tion induces a major significant increase of P-gp cellular level
(+252% ± 68, factorial ANOVA significant at 95%, t-test p <
0.01**).
Figure 7
Effect of cytokines on CNTF-intracellular content
astrocytes. Among all the molecules tested, only LIF and
CT-1 induced a CNTF-modulation in long term astrocyte
culture. Addition of rhLIF during 24 h elicited a significant
increase of P-gp expression both at 10 and 30 ng/ml (+56.12
% ± 25, factorial ANOVA significant at 95%, t-test p < 0.05*
and +33.8 % ± 8, factorial ANOVA significant at 95%, t-test p
< 0.01** respectively). The same pattern of regulation was
observed with CT-1 (+44.5 % ± 12, factorial ANOVA signifi-
cant at 95%, t-test p < 0.01** and +15.1 % ± 5, factorial
ANOVA significant at 95%, t-test p < 0.05*).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/20
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One directly related issue is the role of P-gp in astrocytes.
Taking into account the functions of P-gp in other cells, in
the protection against potentially harmful chemicals and
metabolites, it is plausible that the transporter plays an
important role in the response against cell stress [42], as
suggested by its increase in reactive astrocytes. In addition,
one may consider another role that has been demonstrat-
ed for P-gp and other transporters of the mdr family,
namely their ability to transport various organic mole-
cules through cell membranes, including various cy-
tokines. Indeed, P-gp has been shown to transport
interleukin-2 (IL-2) and interleukin-4 (IL-4) through cell
membranes [9,21,43]. Whether, among other substrates,
P-gp can similarly transport CNTF out of astrocytes is a
tempting hypothesis that will require further studies.
Conclusions
In this study, we have demonstrated a close interaction be-
tween two proteins, CNTF and P-gp. These results suggest
another role for the CNTF in which it could not be neces-
sary for it to be secreted. Indeed, we have shown that an
intrinsic astrocyte P-gp-regulation pathway, in which
CNTF has a predominant role, can trigger biochemical
changes in astrocytes. This pathway is directly related to
the modification of the CNTF-intracellular concentration.
Whether P-gp is the only target of CNTF, or just the first
one identified and whether, among other substrates, P-gp
can similarly transport CNTF out of astrocytes remains to
be seen.
Methods
Astroglial cultures were prepared from cerebral hemi-
spheres of neonatal Swiss mice (Iffa Credo, France) or
CNTF knockout mice (BRL, Switzerland). Cultures were
grown at confluence, for 14 days, thus defining "mature"
cultures as previously described [25].
Recombinant rat CNTF (rrCNTF, Boehringer Mannheim,
Germany), recombinant human Leukemia Inhibitory Fac-
tor and human Cardiotrophin-1 (rhLIF and rhCT-1, Dr
Gascan, Angers), Tumor Necrosis Factor alpha (TNFα ),
Nerve Growth Factor (NGF, Promega, France), Retinoic
Acid (RA, Sigma Aldrich, France), dibutyryl cyclic AMP
(dBcAMP, Sigma Aldrich), bacterial lipopolysaccharides
(LPS, Sigma Aldrich), Transforming Growth Factor alpha
(rhTGFα , Promega, France), recombinant human Inter-
leukin-1β  (rhIL-1β , Sigma), Interferon-β  (IFN-β , Prome-
ga, France), recombinant human Interferon-γ  (rhIFN-γ ,
R&D systems, United Kingdom), recombinant mouse In-
terleukin-6 (rmIL-6, R&D systems, United Kingdom), re-
combinant human soluble Il-6 receptor (R&D systems)
were used in these experiments.
Culture conditions
Astroglial cultures were prepared as previously described
[44]. After 14 days in culture, the astrocytes had formed a
confluent monolayer. Serum containing medium (Mini-
mal Essential Medium containing 2 mM Glutamin, Essen-
tial Amino acids, 0.03% glucose, Penicillin-Streptomycin,
foetal calf serum -FCS- 10%) was removed and serum free
medium added for 24 h. To investigate the effects of vari-
ous factors on P-gp expression, the following compounds
were added for 24, 48 or 72 h: rrCNTF (30, 100, 250 ng/
ml); rhLIF (10, 30 ng/ml); rhCT-1 (10 ng/ml), TNFα  (10,
100 ng/ml), NGF (10 ng/ml), retinoic acid (10-7 M, 10-8
M), dBcAMP (0.5 mM), IFNβ  (600 U/ml), LPS (1 µg/ml),
TGFα  (50 ng/ml), rhIL-1β  (10, 50 ng/ml), rmIL-6 (10, 20,
30, 40, 50 ng/ml) with or without rhsIL-6R (100, 200,
300, 400, 500 ng/ml), rhIFN-γ  (300 U/ml). In the experi-
ments with soluble CNTFRα , 200 ng/ml of myc-sCNTFRα
(kindly provided by Ralph Laufer, IRBM, Italy) were add-
ed to the medium without FCS after 14 days in vitro. Thirty
minutes later, rrCNTF was added at 0, 10 (4.4 ×  10-10 M),
30, 50 (2.2 ×  10-9 M), 100 or 250 ng/ml (10-8 M).
Verapamil (5 µM, Sigma) and S9788 (10 pM, Servier,
France) were used as blockers of P-gp. They were added in
the culture medium 12 h before rrCNTF, rhCT-1 and rh-
LIF, used at the concentrations indicated above.
Since our preliminary results suggested that ligands of the
LIF-receptor (LIFR) may modulate P-gp, a specific inhibi-
Figure 8
Tentative mechanistic model of P-gp regulation by
CNTF based upon the results of the present study.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/20
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tor of this receptor (hLIF05) [45] was added to the culture
medium in some experiments (0.5 and 5 µg/ml), 30 min
before addition of potential stimulating agents. MES-SA/
MX2 cells (ATCC, Biovalley, France) were used as a con-
trol. This cell line is a mitoxanthrone-resistant derivative
of the human uterine sarcoma cell line MES-SA, that dis-
plays features of overexpression of the two classical multi-
drug resistance P-gps. The cells were cultured in a medium
containing 1:1 mixture of Waymouth's MB 752/1 medi-
um and McCoy's 5 a medium, 90%, foetal bovine serum,
10%.
In all cases, the medium was removed at the end of the ex-
periments and each dish was rinsed three times with HBSS
(Hank's Balanced Salt Solution, Seromed, Germany). The
cells were collected by scraping into 62.5 mM Tris HCl
(pH 6.8), 2 mM EDTA, 2 mM phenylmethylsulfonyl fluo-
ride, 0.5 % Triton X-100 and 2.3 % sodium dodecyl sul-
fate.
Biochemical analysis
Total protein content was determined by the BCA protein
assay kit (Pierce, Illinois, USA) with bovine serum albu-
min as a standard. The proteins were analysed by Western
blotting. Briefly, samples were boiled for 5 min after addi-
tion of 10 % glycerol, 5 % mercaptoethanol (or 5 % Dithi-
otreitol for the MAPK-P) and 5 % bromophenol blue,
then lysates were electrophoresed on 7.5% SDS polyacry-
lamid gels. Gels were blotted on nitrocellulose, blocked
for one hour in 5 % non fat dry milk in TBS-T (20 mM
Tris, pH 7.5/ 500 mM NaCl/0.1% Tween 20) and then
probed overnight at 4°C, first with a polyclonal anti-P-
glycoprotein antibody (mdr, Ab-1, Immunotech, France,
1/200), then with a monoclonal anti-α  tubulin antibody
(Sigma-Aldrich, France, 1/5000). After washing with TBS-
T, membranes were incubated with a horseradish peroxi-
dase-conjugated donkey anti-rabbit secondary antibody
followed by the enhanced chemiluminescent reaction
(Amersham, Sweden), according to the manufacturer's in-
structions. The levels of P-gp were measured by densitom-
etry and normalised to the total protein loaded in each
lane.
To limit variations in their processing extracts from the
control and all experimental conditions were treated in
parallel, on a single sheet, for each specific experiment. In
addition, to evaluate the variability between specific ex-
periments, control extracts were subsequently reloaded
together on a single nitrocellulose membrane and proc-
essed together. Statistical analysis used one-factor ANOVA
and unpaired t-test.
PCR experiment
For RT-PCR, RNA isolation was performed with the Trizol
method (Life technologies, Cergy-Pontoise, France). PCR
was carried out with cDNA derived from 2 µg of RNA, 2.5
unit of AmpliTaq Polymerase and reaction kits (Super-
script preamplification systems, Gibco BRL, France) in a
final volume of 50 µl. Each cycle of PCR included 30 sec
of denaturation at 94°C, 1 min of primer annealing at
55°C, and 2 min of extension/synthesis at 72°C and one
cycle of 72°C for 10 min. MDR1-specific sequences were
amplified by using the sense-strand primer CCCATCATT-
GCAATAGCAGG (residues 2596–2615) and the anti-
sense-strand primer GTTCAAACTTCTGCTCCTGA
(residues 2733–2752) [46], which yield a 167-bp prod-
uct. Each primer was added at 10 µM per reaction.
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